Nanjing Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NANJING
NANJING has five approved drugs.
There is one US patent protecting NANJING drugs.
There are nine patent family members on NANJING drugs in five countries and eleven supplementary protection certificates in eight countries.
Summary for Nanjing
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Nanjing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing King Friend | NICARDIPINE HYDROCHLORIDE | nicardipine hydrochloride | INJECTABLE;INJECTION | 216819-001 | Aug 20, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing Delova | QAMZOVA | meloxicam | SOLUTION;INTRAVENOUS | 217593-001 | Apr 22, 2025 | RX | Yes | Yes | 12,059,423 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Nanjing King Friend | PROPOFOL | propofol | INJECTABLE;INJECTION | 217945-001 | Dec 2, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing | CELECOXIB | celecoxib | CAPSULE;ORAL | 213598-001 | May 13, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing King Friend | LIRAGLUTIDE | liraglutide | SOLUTION;SUBCUTANEOUS | 218115-001 | Apr 2, 2025 | AP1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nanjing Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 116327959 | ⤷ Start Trial |
| Japan | 2021521212 | ⤷ Start Trial |
| South Korea | 102843054 | ⤷ Start Trial |
| China | 110464846 | ⤷ Start Trial |
| China | 116327960 | ⤷ Start Trial |
| Japan | 7374501 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nanjing Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2209800 | C300698 | Netherlands | ⤷ Start Trial | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
| 0731795 | 10075033 | Germany | ⤷ Start Trial | PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203 |
| 0944648 | 09C0054 | France | ⤷ Start Trial | PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630 |
| 2597103 | 2017/015 | Ireland | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912 |
| 2209800 | 132014902311502 | Italy | ⤷ Start Trial | PRODUCT NAME: INSULINA DEGLUDEC/LIRAGLUTIDE(XULTOPHY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/947, 20140918 |
| 2209800 | 1490067-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
